|  | Cancer | Testicular Cancer

Bilateral Testicular Tumors: Synchronous vs. Metachronous, Treatment & Prognosis

Bilateral testicular tumors are malignant germ cell tumors occurring in both testes, either simultaneously (synchronous) or sequentially (metachronous). They represent 1–3% of all testicular cancers.

Classification

  • Synchronous: Both tumors diagnosed within 6 months (often at initial presentation).
  • Metachronous: Second tumor diagnosed >6 months after the first (median 2–5 years).

Risk Factors

  • Genetic: KITLG, SPRY4, BAK1, TERT, ATF7IP GWAS loci; family history (father/brother ↑ risk 4–6×).
  • Prior germ cell tumor (highest risk for metachronous contralateral tumor).
  • Testicular dysgenesis syndrome (cryptorchidism, hypospadias, infertility).

Management

  1. Radical inguinal orchiectomy of affected testis (both if synchronous).
  2. Staging: CT chest/abdomen/pelvis, serum tumor markers (AFP, hCG, LDH).
  3. Adjuvant therapy per stage/histology:
    • Stage I: Surveillance (preferred), adjuvant chemo (1 cycle BEP), or RPLND.
    • Stage II–III: Multi-agent chemo (BEP × 3–4 cycles or EP × 4).
  4. Contralateral testis: If preserved (metachronous or organ-sparing attempt), biopsy at orchiectomy (look for GCNIS). If GCNIS+, options: radiotherapy (20 Gy), surveillance, or delayed orchiectomy.

Fertility & Hormonal Considerations

  • Bilateral orchiectomy → permanent hypogonadism → lifelong testosterone replacement.
  • Sperm banking before any treatment is critical.
  • Testicular tissue cryopreservation (experimental) for prepubertal boys.

Prognosis

Excellent overall (>95% 5-year survival) with modern cisplatin-based therapy. Metachronous tumors have similar stage-for-stage outcomes. Long-term surveillance for second malignancies, cardiovascular disease, and hypogonadism is essential.

Testicular Cancer - Related Articles